gastrointestinal surgery (stomach, intestines, liver, gallbladder, pancreas, etc.)
Conditions
Interventions
Control Group (Sufentanil Group):The experimental group received sufentanil intravenously
Experimental Group (Anruifen Group):The experimental group was administered Anruifen intravenously.
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. ASA physical status classification ?-?; 2. Patients scheduled for elective laparoscopic abdominal surgery (including gastrointestinal surgery, hepatobiliary surgery, pancreatic surgery, etc.); 3. Aged 18-75 years; 4. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy or contraindication to Anruikafen, Sufentanil, or other anesthetic drugs used in the study (e.g., Propofol, Cisatracurium); 2. Long-term use of opioid drugs (e.g., for chronic pain management, defined as regular use of opioids for more than 3 months before surgery); 3. Use of medications affecting gastrointestinal motility within 1 week prior to surgery (e.g., gastrointestinal prokinetics, anticholinergic drugs); 4. Pre-existing diseases severely affecting gastrointestinal function, such as: active inflammatory bowel disease (Crohn’s disease, ulcerative colitis); intestinal obstruction, paralytic ileus; severe gastroparesis; prior major abdominal surgery (e.g., gastric bypass, total gastrectomy) potentially leading to anatomical alterations and functional abnormalities; 5. Severe cardiopulmonary dysfunction (e.g., severe heart failure, acute exacerbation of chronic obstructive pulmonary disease), hepatic or renal failure (e.g., decompensated liver cirrhosis, uremia); presence of central nervous system disorders (e.g., epilepsy, severe cognitive impairment) that may affect pain assessment or judgment of postoperative adverse reactions; 6. Emergency surgery or trauma surgery; 7. Severe intraoperative complications (e.g., massive hemorrhage, shock, requirement for massive blood transfusion, abnormally prolonged surgical duration); 8. Unavoidable enterostomy performed during surgery or requirement for prolonged postoperative mechanical ventilation support in the ICU (>24 hours); 9. Pregnant or breastfeeding women; 10. Inability to cooperate with postoperative follow-up (e.g., long-term residence outside the area, communication difficulties); 11. Participation in another clinical drug trial within the recent period (e.g., within 3 months);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first anal flatus after surgery; Time to first anal defecatio n after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Resting Visual Analogue Scale (VAS) Pain Score;I-FEED Score;Incidence of Postoperative Ileus, POI;Time to First Oral Feeding;Postoperative Nausea and Vomiting;Hospitalization Costs and Length of Hospital Stay; | — |
Countries
China
Contacts
Public ContactMo Guixi
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed